Inclusie ER+HER2- MBC met indicatie voor chemotherapie Nog voldoende ruimte voor anthracyclines, ook met eerdere adjuvante kuren meeberekend Sequentieel monotherapie heeft de voorkeur boven combinatie schema’s bij MBC,…
Inclusie HER2 negatief MBC met indicatie voor chemotherapie Nog voldoende ruimte voor anthracyclines, ook met eerdere adjuvante kuren meeberekend. Sequentieel monotherapie heeft de voorkeur boven combinatie schema’s bij…
ImmunoPET imaging with 89Zr-MPDL3280A in patients with locally advanced or metastatic non-small cell lung cancer, bladder cancer or triple-negative breast cancer prior to MPDL3280A treatment. Protocolnummer: MPDL3280A-img-04205 EudraCT…
MPDL3280A treatment in patients with locally advanced or metastatic non-small cell lung, bladder and triple negative breast cancer after investigational imaging. Protocolnummer: ML29755 EudraCT nummer: 2015-000907-19 METc nummer:…
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer –…
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast…
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable locally advanced or metastatic…
Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast…
An open-label, phase I/IIA study of GDC-0810 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer (GO29642) SERD Genentech Protocolnummer: GO29642 Eudract nummer: 2014-004852-77…
Active Immunotherapy PAClitaxel: A multicentre, Phase IIb, randomized, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive…
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer METcnummer: 2013/146 EudraCT nummer: 2013-000551041 Samenvatting Mogelijk zijn…